Spread | 0.2342 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 0.01 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 6.8429 |
Open | 6.7929 |
1-Year Change | 3145.53% |
Day's Range | 6.5529 - 6.9529 |
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).
FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.